On March 22, 2023, neurotechnology company Cognito Therapeutics announced a $73 million Series B financing round. The financing was led by FoundersX Ventures with participation from all its existing investors. The round also included support from new investors Alzheimer’s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and WS Investment Company. Wilson Sonsini Goodrich & Rosati advised Cognito on the transaction.

The new funding round brings Cognito’s total amount raised since inception to $93 million. Cognito plans to use proceeds from the financing to advance its pivotal study of its non-invasive neuromodulation device, which delivers proprietary gamma frequency light and sound stimulation intended to treat Alzheimer’s Disease.

The team that advised Cognito on the transaction included:

Corporate
Mark Fitzgerald
Priyanka Nawathe
Reilly Clark
Rebecca Fliegel

Technology Transactions
Ian Edvalson

Patent
Vern Norviel
Adrian Barker
Lauren Beausoleil

For more information, please read the company’s press release or media coverage on Mobi Health News.